Kidney cancer: The Cytokine Working Group experience (1986-2001): Part II: Management of IL-2 toxicity and studies with other cytokines

Medical Oncology

Volumn 18, Issue 3, 2001, Pages 209-219

  Bhella, David ^a   Rixon, Frazer J ^a   Dargan, Derrick J ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Cytokines; Kidney cancer; Renal cell cancer; Treatment

Indexed keywords

ALPHA INTERFERON; ALPHAN1 INTERFERON; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BICARBONATE; CYTOKINE; DIPHENHYDRAMINE; DIURETIC AGENT; DOPAMINE; EMOLLIENT AGENT; GABAPENTIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYZINE; HYPERTENSIVE FACTOR; INDOMETACIN; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; ONDANSETRON; PARACETAMOL; PETHIDINE; PHENYLEPHRINE;

ARTICLE; BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CAPILLARY LEAK SYNDROME; CARDIOTOXICITY; CHILL; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; FEVER; FLU LIKE SYNDROME; GASTRITIS; GASTROINTESTINAL SYMPTOM; HOSPITAL CARE; HUMAN; HYPOTENSION; HYPOTHYROIDISM; INFECTIOUS COMPLICATION; KIDNEY CANCER; LIVER DYSFUNCTION; LUNG EDEMA; LYMPHOKINE ACTIVATED KILLER CELL; METABOLIC ACIDOSIS; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OUTPATIENT CARE; PRIORITY JOURNAL; SKIN TOXICITY;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS;

EID: 0035192488     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:18:3:209     Document Type: Article

References (43)

1. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines
2. The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells
3. Cardiorespiratory effects of immunotherapy with interleukin-2
4. Chest roentgenographic abnormalities in interleukin-2 recipients: Incidence and correlation with clinical parameters
5. Acute renal dysfunction during interleukin-2 treatment: Suggestion of an intrinsic renal lesion
6. PII. A distinct coagulopathy associated with interleukin-2 therapy
7. Effects of interleukin-2 administration on platelet function in cancer patients
8. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy
9. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells
10. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment
11. Identification of a T-cell-derived B cell growth factor distinct from interleukin-2
12. Nomenclature of lymphokines which regulate B-lymphocytes
13. Interleukin-4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma
14. Interleukin-4 alone and with gamma-interferon or tumor necrosis factor inhibits cell growth and modulates cell surface antigens on human renal cell carcinomas
15. Doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparent non-immunogenic tumors and induce a tumor-specific immune memory
16. I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy
17. Recombinant human IL-4 in advanced renal cancer and malignant melanoma
18. Interleukin-6: An overview
19. The biology of interleukin-6
20. Interleukin-6 and its receptor, a paradigm for cytokines
21. Interleukin-6: Multifunctional cytokine
22. Antitumor activity of recombinant interleukin-6 in mice
23. Cellular mechanisms of the antitumor activity or recombinant IL-6 in mice
24. Phase I trials of intravenous interleukin-6
25. A phase II study of a 120-hour continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma
26. Morphologic and ultrastructural evidence for interleukin-6 induced platelet activation
27. Alterations in platelet function in patients receiving interleukin-6 as cytokine therapy
28. Interleukin 12: A cytokine produced by antigen presenting cells with immunoregulatory functions in the generation of T helper cells type 1 and cytotoxic lymphocytes
29. Interleukin 12
30. Interleukin 12: A key modulator of immune function
31. Antitumor and antimetastatic activity of interleukin-12 against murine tumors
32. Role of interferon - Gamma in mediating the antitumor efficacy of interleukin-12
33. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production
34. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: Response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells
35. Phase I evaluation of intravenous recombinant human interleukin-12 in patients with advanced malignancies
36. Effects of single-dose interleukin-12 (IL-12) exposure on IL-12-associated toxicity and interferon-gamma production
37. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses
38. A pilot/dose-finding study of interleukin-12 administered to patients with AIDS-associated Kaposi's sarcoma
39. Kaposi's sarcoma. New treatment modalities
40. Phase I trial of twice weekly intravenous interleukin-12 in patients with metastatic renal cell cancer or malignant melanoma: Ability to maintain IFN-γ induction is associated with clinical response
41. A T-cell selective interleukin-2 mutein exhibits potent antitumor activity and is well tolerated in vivo
42. Randomized controlled trial of adjuvant therapy with lymphoblastoid interferon in resected high-risk renal cell carcinoma
43. A randomized phase III trial of high-dose interleukin-2 (IL2) versus subcutaneous IL2/interferon in patients with metastatic renal cell carcinoma